Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Matthias Augustina Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyCorrespondence[email protected]

Audrey Nosbaumb Department of Allergy and Clinical Immunology, Hospices Civils de Lyon, Centre Hospitalier, Lyon Sud, France

Thomas Werfelc Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

Susanne Grondd Eli Lilly and Company Ltd, Indianapolis, IN, USA

Catherine Reedd Eli Lilly and Company Ltd, Indianapolis, IN, USA

Anastasia Lampropouloud Eli Lilly and Company Ltd, Indianapolis, IN, USA

Nicole Tietzd Eli Lilly and Company Ltd, Indianapolis, IN, USA

Alan D. Irvinee Dermatology Clinic, Our Lady’s Children’s Hospital Crumlin, Dublin, Ireland

Elisabeth Riedlf Department of Dermatology, Medical University of Vienna, Vienna, Austria

show all

Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date